🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Updated OS for Mariposa study. 8 percent improvement in OS. HR of 0.77 P value of 0.019 . ( not significant as value of less than 0.00001 was needed for statistical significance- read foot note ) But curves are separating nicely . For intracranial PFS , HR of 0.82 . Not

Forever grateful for your support! 🙏

I am so thrilled to have presented an abstract at the #WCLC2024! Heartfelt thanks to the chairs of the session Dr Ullas Batra and Melody Qu. Grateful to my mentors for their guidance! 🙏🧿

A picture with one of the conference chairs of #WCLC2024. Such an inspiring personality, Sandip Patel MD FASCO!

Had a great discussion with Dr Ullas Batra from #India and Ramila Shama from #Nepal! We need a future collaboration to better understand #Cancer outcomes in the #SouthAsian population. A true hope to create a #GlobalOncology project! gilberto lopes Aakash Desai, MD, MPH, FASCO

#ESMO24 Stage 1 TNBC treatment algorithm From David Cescon's wonderful presentation👇

There are certain consequences of conducting clinical trials not based on a rational hypothesis but with the goal of gaining market presence: an example👇 7,305 patients, costing more than $700 million. How will this cost be covered? Of course, by the high price of a drug with

Pramesh CS presentation at #WCC2024 was truly inspiring. As the key figure behind NationalCancerGrid he explained how they're setting uniform cancer care standards across India—pioneering change in treatment, education, and research. #CancerCare Union for International #CancerControl

"Nothing about us without us" is something that the NationalCancerGrid and CReDO strongly believes in. Don't miss this talk by Richard Stephens on "Patient and public involvement in research". For anybody involved in biomedical research, this is not to be missed.

I am excited to share that our study has been published in ecancer. Huge thanks to everyone involved. I am grateful to all of you! #ecancer CReDO ecancer.org/en/journal/art…

“When Less Is Truly More” Excited to share our work from Med Onc CMC Vellore (Official) published in JCO Global Oncology "Does adding low dose Nivo to NACT ⬆️response rates & survival in stage III non-oncogene-driven NSCLC?" 🔗doi.org/10.1200/GO-24-… Mentor Ashish Singh Key findings👇🧵#LCSM

Landmark OS data from #CheckMate816 just dropped in NEJM! 🫁 Neoadjuvant #Nivolumab + chemo in resectable #NSCLC delivers: ✅ 5-yr OS: 65.4% vs 55.0% ✅ HR: 0.72 (p=0.048) ✅ Lung cancer–specific survival HR: 0.65 ✅ OS with pCR: 95.3% ✅ ctDNA clearers: 75%+ OS 📌 No lung

Dr. Patrick Forde presents final OS results from CheckMate 816 at #ASCO25. Adding nivolumab to 3 cycles of neoadjuvant chemotherapy for resectable NSCLC improves OS with HR 0.72 and 5y OS rate 65% vs 55%. Effect greater in PDL1+ (HR 0.51) than PDL1 negative (HR 0.89).

🚨 Wow! #ASCO25 ASCO was absolutely massive! 10 NEJM papers published simultaneously 👉 all practice-changing studies ! 🔬✨🧵 See below for these studies 👇@oncoalert

Just out! New IMS/ IMWG Definition of High Risk Myeloma. Journal of Clinical Oncology #IMWG25 Myeloma Society International Myeloma Foundation Nikhil C. Munshi, MD marivi mateos Sagar Lonial MD Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Noopur Raje

🫁 Summary of immunotherapies early stage NSCLC 1/3 ⭐️ Key clinical data as of June 2025 ※ #ASCO25 data included.

When you treat metastatic CRPC in elderly person, polypharmacy and drug to drug interactions needs to noted . These are some common drug interactions with Abiraterone and Enzalutamide. Useful for clinical practice OncoAlert Kate Sears Oncology Brothers Yakup Ergün

Unique opportunity to hone your knowledge & skills in cancer research methods - last date to apply for the CReDO 15th Jul 2025 Organized by NationalCancerGrid Details at credo.ncgindia.org Apply at credo.ncgindia.org/apply (1/2)

Gonzalo Sapisochin, presented as a surgeon located in Bareclona, reviewed the treatment of localised gallbladder cancer #ESMOGI25 #ESMOAmbassadors ESMO - Eur. Oncology